Biosyent Inc. · TSXV:RX
Biosyent — Q4 2025 Earnings Presentation
24 slides from Biosyent's earnings presentation, Mar 19, 2026
Slide 1: Q4/FY 2025 Results
BioSyent BioSyentInc. Inc. Q4 / FY 2023 Q4/FY 2025 Results Results MARCH MARCH13, 19,2024 2026 PRESENTED BY: RENÉ GOEHRUM PRESENTED BY: RENÉ GOEHRUM PRESIDENT AND CEO PRESIDENT AND CEO 1 | www.biosyent.com | TSXV: RX 1 | www.biosyent.com | TSXV: RX
Slide 2: Disclaimer
DISCLAIMER This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-looking statements
Slide 3: 3 | www.biosyent.com | TSXV: RX | www.biosyent.com | TSXV: RX
3 | www.biosyent.com | TSXV: RX 3 | www.biosyent.com | TSXV: RX
Slide 4: Sales, EBITDA and NIAT (Q4)
Sales, EBITDA and NIAT Quarter ended December 31st (Q4) 10,000 +10% Sales growth from Canadian Pharma, International Pharma and Legacy Businesses CAD (000's) 5,000 EBITDA(1) Margin: 26% to Sales +13% +23% NIAT Margin: 21% to Sales 8,274 1,650 1,451 8,797 2,241 1,613 9,672 2,529 1,992 0 Q4 2023 Q4 20
Slide 5: Sales, EBITDA and NIAT (Full Year)
Sales, EBITDA and NIAT Full Year ended December 31st (FY) 45,000 +23% Sales growth from Canadian Pharma, International Pharma 40,000 and Legacy Businesses 35,000 30,000 25,000 EBITDA(1) Margin: 28% to Sales CAD (000's) 20,000 15,000 +30% NIAT Margin: 21% to Sales 10,000 +24% 31,590 35,031 43,052 12,
Slide 6: Q4/FY 2025 Sales Summary ($)
Q4/FY 2025 Sales Summary ($) Q4 ’25 Q4 ‘25 vs. FY ’25 FY ‘25 vs. Sales ($) Q4 ’24 (%) Sales ($) FY ’24 (%) Canadian Pharma ($) $8,793k +3% $37,144k +13% Cathejell® -3% +3% Combogesic® +5% -18% FeraMAX® Pd +1% +12% Gelclair® -15% -39% $2.4 Million in additional Inofolic® +68% +64% 2025 sales contribu
Slide 7: Fully Diluted Earnings per Share (TTM)
Fully Diluted Earnings per Share (TTM) TTM and Quarterly Fully Diluted EPS (CAD) 0.80 62 Consecutive 0.78 0.70 Profitable Quarters to Q4 2025 0.62 0.60 0.54 0.50 0.40 0.30 0.20 0.23 0.20 0.20 0.20 0.18 0.14 0.17 0.15 0.13 0.12 0.12 0.10 0.10 0.00 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 20
Slide 8: 2025 Highlights
2025 Highlights FY 2025: First Tibelia® Global shipments made by BioSyent: ~$2.4 million in incremental revenue Further orders shipped in Q1 2026 Mar/Jun/Sep/Dec 2025: Paid quarterly dividends of $0.05/share (+11% increase vs. 2024) Apr 2025: FeraMAX® named #1 recommended iron supplement in
Slide 9: YTD 2026 Highlights
YTD 2026 Highlights Mar 1, 2026: Completed Acquisition of Oral Science Inc. Mar 13, 2026: Paid quarterly dividend of $0.055/share (+10% increase vs. 2025) 9 | www.biosyent.com | TSXV: RX
Slide 10: Geopolitics, Trade and Economy
Geopolitics, Trade and Economy Uncertainty Armed conflicts Tariffs / Counter-Tariffs Inflationary impacts Impact on supply chains, global trade and economies 10 | www.biosyent.com | TSXV: RX
Slide 11: Acquisition of Oral Science
Acquisition of Oral Science Acquisition by BioSyent Inc. of Privately-Owned Canadian Distributor of Specialized Healthcare Products for Dental Hygiene and Oral Health Share Purchase Agreement (SPA) closed on March 1, 2026 100% of issued Oral Science shares acquired from Shareholders, Founders of
Slide 12: Oral Science Overview
Oral Science Overview Growing, revenue-stage oral health company with a successful track record of developing, sourcing, marketing and distributing innovative dental hygiene and oral health products Founded in 2003 54% of sales from Canadian dental clinics 46% of sales from consumers at retail
Slide 13: Strong Balance Sheet for Future Growth
Strong Balance Sheet for Future Growth Financing of Acquisition Balance Sheet Assets – Pre and Post Closing $25.5M Purchase Price + $2.0M Excess WC 35 $16.3M Liquid Cash 30 $ 8.0M Debt 25 $6.0M Term Loan $2.0M Revolving Line Draw 20 $3.0M Common Shares 15 $0.2M RSUs 10 Debt expected to
Slide 14: Strategic Rationale for Acquisition of Oral Science
Strategic Rationale for Acquisition of Oral Science Transaction builds substantial scale in BioSyent’s revenue and profit Strategic use of capital to accelerate growth and enhance resilience Derisks the business model with immediate diversification of BioSyent business, with new platform in tangenti
Slide 15: Going Forward
Going Forward BioSyent will continue to invest in future growth of pharmaceutical + oral health platforms 15 | www.biosyent.com | TSXV: RX
Slide 16: Most recommended iron supplement in Canada
Most recommended iron supplement in Canada - pharmacists and physicians - 10 consecutive years(1) Continued innovation and expansion of FeraMAX® product line for iron health (1) Based on Pharmacy Practice + Business, The Medical Post and Profession Santé 2025 Survey on OTC Counselling and Recomm
Slide 17: Innovations, Product Launches and Acquisitions
Innovations, Product Launches and Acquisitions Tibella® Jul 2020 FeraMAX® Pd Oct 2020 FeraMAX® Pd Therapeutic 150 Nov 2020 Combogesic® Dec 2020 FeraMAX® Pd Powder 15 Oct 2021 FeraMAX® Pd Maintenance 45 Mar 2023 Inofolic® Aug 2023 Gelclair® Nov 2023 Tibelia® Global Sep 2024 Oral Science Mar 2026 New
Slide 18: 16 Years of Profitable Growth (and Counting!)
16 Years of Profitable Growth (and Counting!) 50,000 Annual Revenue Annual NIAT Tibelia Global 45,000 40,000 2010 – 2025 Growth: Revenue 26x 35,000 NIAT 173x 30,000 CAD 000'S 25,000 20,000 15,000 10,000 5,000 0 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 *2026* f/
Slide 19: ProForma 2025 with Oral Science
ProForma 2025 with Oral Science 80,000 Annual Revenue (BioSyent) Annual NIAT Tibelia Global 70,000 60,000 50,000 CAD 000'S 40,000 30,000 20,000 10,000 0 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 *2026* f/d shares: 14,336,194 11,831,378 19 | www.biosyent.com | TS
Slide 20: Cash Balance & Return on Equity
Cash Balance & Return on Equity (“RoE”) Full Year ended December 31 35,000 24% 25% • 2025 Cash from Operations; 19% $9.0M 21% 30,000 31,946 27,785 20% • 2025 NCIB share buybacks: 25,000 26,045 $0.2M 20,000 15% • 2025 Net Dividends: $2.3M CAD (000's) RoE % 15,000 10% • Dec 31/25 Working Capital of $3
Slide 21: Capital Allocation linked to Strategy
Capital Allocation linked to Strategy First use of capital is to generate revenue/profit growth & portfolio diversification. Capital Light, Cash-Generating Quarterly Dividends Business Model $6.9 M to Date Q4’22 – Q1’26 Share Buybacks $22.6 M to Date 3.1 million shares repurchased since 2018 •7 new
Slide 22: Stock Information
Stock Information As at March 18, 2026 Exchange & Trading Symbol 0% TSXV: RX Mar 18, 2026 Closing Stock Price (CAD) (TSXV): $15.31 52 Week Hi/Low (TSXV): $15.80 / $9.20 Issued Common Shares: 11,709,639 Treasury – RSU Shares in Trust (212,192) Outstanding Common Shares: 11,497,447 Options Outstanding
Slide 23: Reconciliation of EBITDA to NIAT
Reconciliation of EBITDA to NIAT 1. EBITDA is a Non-IFRS Financial Measure. The term EBITDA does not have any standardized meaning under International Financial Reporting Standards (IFRS) and therefore may not be comparable to similar measures presented by other companies. The Company defines EBITDA
Slide 24: Profitable. Well Capitalized. Growth Assets.
PROFITABLE. WELL CAPITALIZED. GROWTH ASSETS. FOCUSED ON LONG-TERM GROWTH AND TOTAL SHAREHOLDER RETURN. 24 www.biosyent.com | TSXV: RX